Pasithea Therapeutics Corp Announces Grant of Rare Pediatric Disease Designation by FDA to Pas-004 for Treatment of Neurofibromatosis Type 1 Apr 21
Pasithea Therapeutics Corp Announces Grant of Fast Track Designation by Fda to Pas-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity Apr 01
Pasithea Therapeutics Corp. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing Rule Feb 21
Pasithea Therapeutics Provides Outlook on Pas-004 Clinical Programs and Data Release Timelines Jan 13
Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $59.934847 million. Dec 02
Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering. Nov 27
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data Nov 25
New minor risk - Share price stability Nov 20
Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $10 million. Nov 19
Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Site At University of Alabama At Birmingham for Ongoing Phase 1/1B Trial of Pas-004 in Adult Nf1 Patients Nov 06
Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients Sep 16
Pasithea Therapeutics Corp. Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients Sep 08
New major risk - Financial position Aug 15
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients Jul 31
Pasithea Therapeutics Corp., Annual General Meeting, Sep 03, 2025 Jul 16
Pasithea Therapeutics Receives Nasdaq Non-Compliance Notice Regarding Minimum Bid Price Requirement Jun 29
Pasithea Therapeutics Appoints James Lee to Scientific Advisory Board Jun 11
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 At the ASCO Annual Meeting 2025 Jun 02
Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases May 20
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site May 15
Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.999522 million. May 09
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 May 08
Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering. May 01
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients Apr 30
Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting Apr 24
Pasithea Therapeutics Corp. Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Apr 13
New major risk - Shareholder dilution Mar 26
New major risk - Financial position Mar 25
New minor risk - Share price stability Feb 05
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation from Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer Feb 05
Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $2.076 million. Nov 27
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Nov 20
New major risk - Financial position Nov 15
Pasithea Therapeutics Corp. announced that it has received $5.000003 million in funding Oct 01
Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding Sep 27
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board Sep 03
New minor risk - Share price stability Jul 30
Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial Jun 15
Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024 May 17
Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers Apr 25
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004 Feb 14
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position Jan 10
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients Jan 02
New major risk - Financial position Nov 20
Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate Nov 10
Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023 Oct 27
High number of new and inexperienced directors Oct 20
Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery Program Aug 02
New major risk - Share price stability Jul 21
Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million. Jun 07
Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement Jan 26
Concord IP2 Recommends Stockholders to Vote for Boardroom Change at Pasithea Therapeutics Dec 08
Price target decreased to US$2.30 Nov 16
Less than half of directors are independent Nov 16
Concord IP2 Ltd Files a Lawsuit Against the Directors of Pasithea Therapeutics Corp Nov 02
Camac Partners Comments on Pasithea Therapeutics’ Acquisition of AlloMek Therapeutics Oct 14
Camac Partners LLC Sends a Letter to Pasithea Therapeutics Corp Sep 30
Less than half of directors are independent Sep 23
Pasithea Therapeutics Corp. Appoints Alfred J. Novak to Its Board of Directors Sep 21
Pasithea Therapeutics Corp. Appoints Dr. Merit Cudkowicz to its Scientific Advisory Board Sep 16
Camac Partners Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting Aug 26
Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis Aug 12
Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special Meeting Aug 06
Concord IP2 Ltd Nominates Candidates to the Board of Pasithea Therapeutics Corp Jul 29
Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics Corp Jul 02
Concord IP2 Ltd Provides Information to Shareholders of Pasithea Therapeutics Corp Jun 28
Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp Jun 17
Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp., Passes Away Jun 11
Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics Corp Jun 02
Pasithea Therapeutics Corp., Annual General Meeting, Jun 23, 2022 May 14
Less than half of directors are independent Apr 27
Pasithea Therapeutics Appoints Daniel Weinberger to Its Scientific Advisory Board Feb 10
Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis Feb 04
Pasithea Therapeutics Corp. announced that it has received $30.38 million in funding Nov 30
Pasithea Therapeutics Corp. announced that it expects to receive $30.38 million in funding Nov 26
Pasithea Therapeutics Adds Esketamine Nasal Spray to Its Clinic Offerings in the U.K Nov 24 